- Home
- EYPT vs PLSE Comparison
EYPT vs PLSE Comparison
Compare EYPT & PLSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EYPT | PLSE |
|---|---|---|
| Founded | 1987 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2005 | 2015 |
Fundamental Metrics
Financial Performance| Metric | EYPT | PLSE |
|---|---|---|
| Price | $12.86 | $21.07 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $31.80 | $22.00 |
| AVG Volume (30 Days) | ★ 1.2M | 259.6K |
| Earning Date | 03-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,539,000.00 | N/A |
| Revenue This Year | N/A | $840.00 |
| Revenue Next Year | $1,031.72 | $287.54 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.91 | $12.56 |
| 52 Week High | $19.11 | $26.30 |
Technical Indicators
Market Signals| Indicator | EYPT | PLSE |
|---|---|---|
| Relative Strength Index (RSI) | 36.53 | 54.29 |
| Support Level | $12.05 | $13.75 |
| Resistance Level | $13.32 | $26.30 |
| Average True Range (ATR) | 1.01 | 1.40 |
| MACD | -0.33 | 0.10 |
| Stochastic Oscillator | 3.45 | 62.11 |
Price Performance
Historical ComparisonAbout EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
About PLSE Pulse Biosciences Inc (DE)
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.